title: Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults.
abstract: A Plasmodium falciparum sporozoite vaccine, composed of a synthetic dodecapeptide (NANP)3 coupled to tetanus toxoid (TT), was injected, at weeks 0 and 8, into non-immune volunteers in two randomized double-blind placebo-controlled trials. In the first trial, 37 volunteers received the vaccine simultaneously with placebo (group 1), 0.5 x 10(6-) (group 2), or 1.5 x 10(6) U (group 3) of recombinant human interferon-alpha (= IFN-alpha). In the second trial, 35 other volunteers received the vaccine with placebo (group 4), 0.25 x 10(6) (group 5), or 1.0 x 10(6) IU (group 6) of interferon-gamma (= IFN-gamma). Immunizations were well tolerated and resulted in seroconversion rates (greater than or equal to 4-fold increase of antibody titre in immunofluorescence or enzyme-linked immunosorbent assays) of 67-100% of volunteers. IFN-alpha significantly enhanced the IgG antibody titres in ELISA to malaria peptide.
authors: Clinical Department, F. Hoffmann-La Roche & Co. Ltd., Basel, Switzerland.
authors: D
authors: D
authors: Stürchler
authors: R
authors: R
authors: Berger
authors: H
authors: H
authors: Etlinger
authors: M
authors: M
authors: Fernex
authors: H
authors: H
authors: Matile
authors: R
authors: R
authors: Pink
authors: V
authors: V
authors: Schlumbom
authors: M
authors: M
authors: Just
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007372:Interferons / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000276:immunology*; D010963:Plasmodium falciparum / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic; D013745:Tetanus Toxoid; D014612:Vaccines / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D009842:Oligopeptides; D013745:Tetanus Toxoid; D014612:Vaccines; D014614:Vaccines, Synthetic; D007372:Interferons; C052953:(asparaginyl-alanyl-asparaginyl-proline)3